US Patent

US9907788 — Inhibition of crystal growth of roflumilast

Method of Use · Assigned to Arcutis Inc · Expires 2037-06-07 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition that includes hexylene glycol to inhibit the growth of roflumilast crystals during storage.

USPTO Abstract

Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3712 — Daliresp
U-4301 — Daliresp
U-4203 — Daliresp
U-3970 — Daliresp

Patent Metadata

Patent number
US9907788
Jurisdiction
US
Classification
Method of Use
Expires
2037-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Arcutis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.